Results 291 to 300 of about 177,018 (304)

Cd19(Cd0.2Ni0.8)5

2006
P. Villars, K. Cenzual, J. Daams, R. Gladyshevskii, O. Shcherban, V. Dubenskyy, N. Melnichenko-Koblyuk, O. Pavlyuk, S. Stoiko, L. Sysa   +9 more
openaire   +1 more source

An iPSC-derived CD19/BCMA CAR-NK therapy in a patient with systemic sclerosis

Cell
Xiaobing Wang, Lie Dai, Wenjing Ye
exaly  

CD19‐CAR engineered NK‐92 cells are sufficient to overcome NK cell resistance in B‐cell malignancies

Journal of Cellular and Molecular Medicine, 2016
Gesine Bug, Erhard Seifried, Winfried S Wels   +2 more
exaly  

CD19 (16p11.2)

2008
openaire   +1 more source

In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin’s Lymphomas

Molecular Therapy, 2018
Carlos A Ramos, Rayne H Rouce, Birju Mehta   +2 more
exaly  

MAb CLB-CD19

Inpharma Weekly, 1991
openaire   +1 more source

Development of a Novel Anti-CD19 Chimeric Antigen Receptor: A Paradigm for an Affordable CAR T Cell Production at Academic Institutions

Molecular Therapy - Methods and Clinical Development, 2019
Maria Castella, Miguel Caballero, Berta Marzal   +2 more
exaly  

Anti-CD19 Immunotoxins

2020
openaire   +1 more source

CD19 as an attractive target for antibody-based therapy

MAbs, 2012
exaly  

CD19 wt Allele

2020
openaire   +1 more source